Safety and effectiveness of alectinib in a real‐world surveillance study in patients with ALK‐positive non–small‐cell lung cancer in Japan

We conducted a large‐scale surveillance study as a post–marketing commitment to investigate the safety and effectiveness of alectinib in patients with ALK‐positive non–small‐cell lung cancer (NSCLC) in Japan. Patients receiving 300 mg twice‐daily alectinib (September 2014 to June 2015) were monitore...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Noriyuki, Ohe, Yuichiro, Gemma, Akihiko, Kusumoto, Masahiko, Yamada, Ikuyo, Ishii, Tadashi, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447840/
https://www.ncbi.nlm.nih.gov/pubmed/30776174
http://dx.doi.org/10.1111/cas.13977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447840/
https://www.ncbi.nlm.nih.gov/pubmed/30776174
http://dx.doi.org/10.1111/cas.13977

Ejemplares similares